Financial Highlights

Dividends

Dividends

Five Year Summary

All figures in US$ million unless stated otherwise

 

2016-17
Constant Currency(2)

2016-17
Reported(3)

2015-16
Reported

2014-15
Reported

2013-14
Reported

2012-13
Reported

Total Operating Revenue

7,002

6,923

6,115

5,612

5,504

5,100

Sales Revenue

6,688

6,616

5,909

5,459

5,335

4,950

R&D Investment

643

645

614

463

466

427

Profit before Income Tax Expense

1,958

1,690

1,556

1,714

1,604

1,461

Net profit after tax

1,427

1,337

1,242

1,379

1,307

1,211

Net cash inflow from Operating Activities 

1,247

1,179

1,364

1,361

1,312

Capital investment 

861

566

414

402

450

Return on Invested Capital (%) 

24.5%

26.8%(4)

31.7%

31.8%

32.6%

Basic earnings per share ($)  

2.937

2.689

2.923

2.701

2.429

Dividend per share ($)  

1.360

1.260

1.240

1.130

1.020

(1) For shareholders with an Australian registered address, dividends will be paid in A$ at an amount of A$0.915264 per share (at an exchange rate of A$1.2712/US$1.00), and for shareholders with a New Zealand registered address, dividends will be paid in NZD at an amount of NZ$0.986328 per share (at an exchange rate of NZ$1.3699/US$1.00). 
(2) Constant currency removes the impact of exchange rate movements to facilitate comparability. For further details please refer to the Directors’ Report. 
(3) The Group’s reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(4) 2016 figure includes the gain on acquisition of Novartis' global influenza business of US$176.1 million


Financial Performance in US$

CSL Earnings Per Share 10-11 11-12 12-13 13-14 14-15 1.4 1.8 2.2 2.6 3.0 1.70 1.70 1.97 1.97 2.43 2.43 2.70 2.70 2.92 2.92 (US$ millions)
Year(US$ millions)
10-111.7
11-121.97
12-132.43
13-142.7
14-152.92
CSL R&D Investment 10-11 11-12 12-13 13-14 14-15 300 350 400 450 500 323 323 370 370 427 427 466 466 463 463 (US$ millions)
Year(US$ millions)
10-11323
11-12370
12-13427
13-14466
14-15463
CSL Total Revenue 10-11 11-12 12-13 13-14 14-15 4,000 4,500 5,000 5,500 6,000 4228 4228 4814 4814 5130 5130 5524 5524 5628 5628 (US$ millions)
Year(US$ millions)
10-114228
11-124814
12-135130
13-145524
14-155628
CSL Net Profit 10-11 11-12 12-13 13-14 14-15 900 1,050 1,200 1,350 1,500 918 918 1024 1024 1211 1211 1307 1307 1379 1379 (US$ millions)
Year(US$ millions)
10-11918
11-121024
12-131211
13-141307
14-151379
CSL Group Sales by Major Products (2016-17) 42% 15% 13% 18% 12%
Product%
Immunoglobulins42%
Haemophilia15%
Albumin13%
Specialty18%
Seqirus12%

Dividends and Financial Results

CSL’s reported net profit after tax was US$1,337 million for the year ended 30 June 2017. On a constant currency basis, net profit after tax was US$1,427 million.

On 13 April 2017, CSL shareholders received an interim unfranked dividend of US$0.64 per share. A final unfranked dividend of US$0.72 per share will be paid on 13 October 2017. Total ordinary dividends for the year were US$1.36 per share.

On 12 October 2016, CSL announced an on-market share buyback of up to A$500 million which, as of 30 June 2017, was 70% complete with approximately 2.86 million shares repurchased for A$349.7 million. The benefit to shareholders comes from improved investment return ratios, including earnings per share and return on equity.

CSL business activities reported here include CSL Behring, Seqirus and our global Research and Development (R&D) operations.